[Featured Stock] Anguk Pharm Shows Strength Following MFDS Approval of Phase 3 Clinical Trial for High Cholesterol Patients
[Asia Economy Reporter Minji Lee] Anguk Pharm is showing strength following news that the Ministry of Food and Drug Safety (MFDS) approved its Phase 3 clinical trial targeting patients with hypercholesterolemia.
At 11:38 AM on the 20th, Anguk Pharm was trading at 11,450 KRW, up 5% from the previous session.
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- Dismissal of Seoul National University Professor for Plagiarizing Student's Thesis Deemed Justified... Court: "Higher Ethical Standards Required"
- Experts Are Already Watching Closely..."Target Stock Price 970,000 Won" Now Only the Uptrend Remains [Weekend Money]
- "That? It's Already Stashed" Nightlife Scene Crosses the Line [ChwiYak Nation] ③
Anguk Pharm received approval from the MFDS on the same day after conducting a Phase 3 clinical trial to compare the efficacy of combination therapy with AGT and AGZ in patients with primary hypercholesterolemia.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
